{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=24+Gy&page=2", "query": { "intervention": "24 Gy", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 10, "total_pages": 1, "next_page_url": null, "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=24+Gy&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-09-24T08:12:38.842Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00305864", "title": "Motexafin Gadolinium, Temozolomide, and Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Adult Giant Cell Glioblastoma", "Adult Glioblastoma", "Adult Gliosarcoma" ], "interventions": [ { "name": "3-Dimensional Conformal Radiation Therapy", "type": "RADIATION" }, { "name": "Motexafin Gadolinium", "type": "DRUG" }, { "name": "Temozolomide", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 118, "start_date": "2006-02-09", "completion_date": "2011-03-15", "has_results": true, "last_update_posted_date": "2018-03-05", "last_synced_at": "2026-09-24T08:12:38.842Z", "location_count": 106, "location_summary": "Mobile, Alabama • Scottsdale, Arizona • Tucson, Arizona + 73 more", "locations": [ { "city": "Mobile", "state": "Alabama" }, { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Castro Valley", "state": "California" }, { "city": "Castro Valley", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00305864" }, { "nct_id": "NCT02360215", "title": "Memantine Hydrochloride and Whole-Brain Radiotherapy With or Without Hippocampal Avoidance in Reducing Neurocognitive Decline in Patients With Brain Metastases", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Cognitive Impairment", "Metastatic Malignant Neoplasm in the Brain", "Solid Neoplasm" ], "interventions": [ { "name": "Whole brain radiation therapy with hippocampal avoidance", "type": "RADIATION" }, { "name": "Memantine", "type": "DRUG" }, { "name": "Whole brain radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "NRG Oncology", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 518, "start_date": "2015-07", "completion_date": "2019-08-26", "has_results": true, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-09-24T08:12:38.842Z", "location_count": 212, "location_summary": "Tuscaloosa, Alabama • Gilbert, Arizona • Tucson, Arizona + 172 more", "locations": [ { "city": "Tuscaloosa", "state": "Alabama" }, { "city": "Gilbert", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Burbank", "state": "California" }, { "city": "Carmichael", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02360215" }, { "nct_id": "NCT01490749", "title": "Trial of XELOX Followed by Radiation Combined With Carboplatin and RAD001 for Esophageal Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Esophageal Cancer", "Neoplasms, Esophageal" ], "interventions": [ { "name": "RAD001", "type": "DRUG" }, { "name": "XELOX", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" }, { "name": "Radiation", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Emory University", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2012-02", "completion_date": "2019-02", "has_results": false, "last_update_posted_date": "2019-03-15", "last_synced_at": "2026-09-24T08:12:38.842Z", "location_count": 3, "location_summary": "Atlanta, Georgia • Nashville, Tennessee", "locations": [ { "city": "Atlanta", "state": "Georgia" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT01490749" }, { "nct_id": "NCT05045950", "title": "Optimizing Neurocognition With Whole Brain Radiation Therapy (WBRT) Using Upfront Pulsed Reduced Dose-Rate (PRDR) Technique", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Brain Metastases" ], "interventions": [ { "name": "Memantine -Twice Daily or Extended Release", "type": "DRUG" }, { "name": "WBRT utilizing the PRDR technique", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Medical College of Wisconsin", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 53, "start_date": "2021-11-17", "completion_date": "2029-05", "has_results": false, "last_update_posted_date": "2026-07-29", "last_synced_at": "2026-09-24T08:12:38.842Z", "location_count": 2, "location_summary": "Milwaukee, Wisconsin", "locations": [ { "city": "Milwaukee", "state": "Wisconsin" }, { "city": "Milwaukee", "state": "Wisconsin" } ], "official_url": "https://clinicaltrials.gov/study/NCT05045950" }, { "nct_id": "NCT00561197", "title": "An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Locally Advanced Esophageal or GE Junction Cancer" ], "interventions": [ { "name": "AT-101", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ascenta Therapeutics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2007-08", "completion_date": "2010-09", "has_results": false, "last_update_posted_date": "2013-01-04", "last_synced_at": "2026-09-24T08:12:38.842Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT00561197" }, { "nct_id": "NCT00004859", "title": "Carboplatin, Paclitaxel, and Radiation Therapy With or Without Thalidomide in Patients With Stage III Non-small Cell Lung Cancer", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Lung Cancer" ], "interventions": [ { "name": "carboplatin", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "thalidomide", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 589, "start_date": "2000-01", "completion_date": "2010-03", "has_results": true, "last_update_posted_date": "2014-06-02", "last_synced_at": "2026-09-24T08:12:38.842Z", "location_count": 235, "location_summary": "Fort Smith, Arkansas • Modesto, California • Salinas, California + 168 more", "locations": [ { "city": "Fort Smith", "state": "Arkansas" }, { "city": "Modesto", "state": "California" }, { "city": "Salinas", "state": "California" }, { "city": "Stanford", "state": "California" }, { "city": "Aurora", "state": "Colorado" } ], "official_url": "https://clinicaltrials.gov/study/NCT00004859" }, { "nct_id": "NCT02106988", "title": "Concurrent Chemotherapy and Radiation Therapy for Newly Diagnosed Nasal NK Cell Lymphoma", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "Radiation Therapy", "type": "RADIATION" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Etoposide phosphate", "type": "DRUG" }, { "name": "Ifosfamide", "type": "DRUG" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "RADIATION", "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 26, "start_date": "2015-01-16", "completion_date": "2034-01-31", "has_results": false, "last_update_posted_date": "2026-04-14", "last_synced_at": "2026-09-24T08:12:38.842Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02106988" }, { "nct_id": "NCT02314403", "title": "Renal Allograft Tolerance Through Mixed Chimerism (Belatacept)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Kidney Failure, Chronic", "Renal Insufficiency" ], "interventions": [ { "name": "Belatacept", "type": "DRUG" }, { "name": "ATG", "type": "DRUG" }, { "name": "Rituximab", "type": "DRUG" }, { "name": "Total Body Irradiation", "type": "RADIATION" }, { "name": "Thymic Irradiation", "type": "RADIATION" }, { "name": "Combined Bone Marrow/Kidney Transplantation", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Massachusetts General Hospital", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "60 Years", "sex": "ALL", "summary": "18 Years to 60 Years" }, "enrollment_count": 2, "start_date": "2015-02", "completion_date": "2021-07", "has_results": true, "last_update_posted_date": "2021-10-25", "last_synced_at": "2026-09-24T08:12:38.842Z", "location_count": 1, "location_summary": "Boston, Massachusetts", "locations": [ { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT02314403" }, { "nct_id": "NCT00055601", "title": "Combination Chemotherapy and Radiation Therapy With/Without Surgery In Patients With Stage II/III Bladder Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Bladder Cancer" ], "interventions": [ { "name": "cisplatin", "type": "DRUG" }, { "name": "fluorouracil", "type": "DRUG" }, { "name": "paclitaxel", "type": "DRUG" }, { "name": "radiation therapy", "type": "RADIATION" }, { "name": "Gemcitabine", "type": "DRUG" }, { "name": "Radical cystectomy", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "RADIATION", "PROCEDURE" ], "sponsor": "Radiation Therapy Oncology Group", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": null, "maximum_age": "120 Years", "sex": "ALL", "summary": "Up to 120 Years" }, "enrollment_count": 97, "start_date": "2002-12", "completion_date": "2018-05-14", "has_results": true, "last_update_posted_date": "2018-06-15", "last_synced_at": "2026-09-24T08:12:38.842Z", "location_count": 2, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT00055601" }, { "nct_id": "NCT03474497", "title": "UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Non Small Cell Lung Cancer", "Metastatic Melanoma", "Metastatic Renal Cell Carcinoma", "Head and Neck Squamous Cell Carcinoma" ], "interventions": [ { "name": "IL-2", "type": "DRUG" }, { "name": "Pembrolizumab", "type": "DRUG" }, { "name": "Radiotherapy", "type": "RADIATION" } ], "intervention_types": [ "DRUG", "RADIATION" ], "sponsor": "Megan Daly, MD", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 18, "start_date": "2019-05-20", "completion_date": "2026-02", "has_results": true, "last_update_posted_date": "2026-01-29", "last_synced_at": "2026-09-24T08:12:38.842Z", "location_count": 2, "location_summary": "Sacramento, California", "locations": [ { "city": "Sacramento", "state": "California" }, { "city": "Sacramento", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT03474497" } ] }